Applied Nanoscience Inc., a nanotechnology-based filtration development company, today confirmed an expansion of its technical staff by adding three key positions to ensure a successful production scale-up and supply of the company's proprietary antimicrobial NanoFense technology, a U.S. patent pending nanoparticle formulation.
Nanometrics Incorporated today announced multiple system orders for its Caliper Mosaic overlay metrology systems and its complete NanoCD suite including Atlas OCD systems, NanoDiffract software, and NanoGen cluster computing solutions.
With the introduction of 45-nm and below technologies, the demand for optical proximity correction (OPC) becomes greater due to design complexity and layer volume, making time to market and cost of ownership critical factors in OPC vendor selection.
Asylum Research and Intertech Corporation announced today that they have entered into a new distribution agreement that will enable Asylum to extend its global reach and promote its products in the Russian Federation, Belarus, Georgia, Ukraine, Kazakhstan, Kyrgyzstan, Uzbekistan, Tajikistan, Armenia, and Turkmenistan.
Magma Design Automation Inc., a provider of chip design solutions, announced Magma customers have passed the 50-tapeout mark for chips designed at 45 nanometer or smaller geometries using Magma's Talus netlist-to-GDSII design implementation system - more than with any other EDA supplier-s implementation system.
CopyTele, Inc. announced today that it has entered into an Engagement Agreement with ZQX Advisors, LLC to seek business opportunities and licenses for its electrophoretic display technology (E-paper) and its related intellectual property, particularly its patent portfolio.
Applied Ventures, LLC, the venture capital arm of U.S.-based Applied Materials, Inc., invests in Tera Barrier Films Pte. Ltd., a newly incorporated spin-off from A*STAR's Institute of Materials Research and Engineering.
Following oversubscription of Nano Bridging Molecules SA's first funding round in 2007 NBM significantly expanded its pre-clinical testing program, embarked on its first dental human clinical trial, recruited key scientific and clinical research staff and relocated its operations to purpose built laboratories and new offices in the Swiss canton of Vaud.
PerkinElmer, Inc. announced that it has entered into an exclusive agreement with Max Planck Innovation, the technology transfer organization of the Max Planck Society, for the licensing of its ultra-fast, low cross-talk solid state silicon photomultiplier (SiPM) technology.
This business development advisory committee will be headed by Director Paul Rocheleau and will also include board member Clint Everton and members of management. The committee intends to add other qualified outsiders in the near future.
Nanotherapeutics, Inc. today announced that it has been awarded a $30.9 Million, 5-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop an inhaled version of the injectable antiviral drug, cidofovir, for non-invasive, post-exposure prophylaxis and treatment of the Category A bioterrorism agent smallpox.